[Applicant's name] is submitting this PMA Manufacturing Site Change Supplement to our approved Premarket Approval application for the [present device trade name] to request approval for a new [manufacturing or sterilization] facility. FDA/CDRH/ODE . the site was approved as part of original PMA or PMA supplement, but only for the performance of different manufacturing activities. PMA supplements submitted must include information relevant to the proposed changes in the device. SUBJECT: PMA supplement to [original PMA reference number] for [present device trade name]. The .gov means it’s official.Federal government websites often end in .gov or .mil. In the case of a PMA supplement for a new model or revised indication, specify the indication for use for which FDA approval is requested. [Applicant's name] is submitting this "Special PMA Supplement-Changes Being Effected" to our approved Premarket Approval application to place into effect the following change(s) described in 21 CFR 814.39(d)(2) that enhance(s) the [safety of/safety in the use] of [device trade name]. RESULTS: From 1979-2012, the FDA approved 77 original and 5829 supplement PMA applications for CIEDs, with a median of 50 supplements per original PMA (interquartile range [IQR], 23-87). Amendments (§ 814.37) or supplements (§814.39) are submitted to the Food and Drug Administration (FDA) for changes to the original Premarket Approval (PMA) submission. The existence of this PMA supplement and the data and other information that it contains are confidential, and the protection afforded to such confidential information by 18 USC 1905, 21 USC 331(I), 5 USC 552, and other applicable laws is hereby claimed. Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process Guidance for Industry and FDA Staff December 2008 Such changes will be identified in written correspondence to each PMA holder who may be affected by FDA's decision. Center for Devices and Radiological Health, An official website of the United States government, : A PMA supplement is the submission required for a change affecting the safety or effectiveness of the device for which the applicant has an approved PMA; additional information provided to FDA for PMA supplement under review are amendments to a supplement. For significant change in components, materials, design, specification, software, color additves, or labeling. FDA will notify applicants of this alternative through an advisory opinion to the affected industry or in correspondence with the applicant. All changes must meet the requirements of the Quality System regulation (current good manufacturing practices) under 21 CFR Part 820 including the design control requirements under §820.30. If the 30-day Notice was not adequate, but contained data meeting appropriate content requirements for a PMA supplement, then the 30-day Notice will become a 135-day PMA Supplement. For the use of a different facility or establishment to manufacture, process, or package the device. Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency The FDA released a new guidance document on May 21, 2020 addressing manufacturing limitations or supply chain issues due to disruptions being caused by the COVID-19 public health emergency. The completion of this Premarket Submission Coversheet (Form FDA 3514) is voluntary and will not affect any Food and Drug Administration (FDA) decision concerning your submission, but will help FDA's Center for Devices and Radiological Health process your submission more efficiently by placing administrative data elements in a consistent format for data entry purposes. The guidance also explains what FDA considers to be a manufacturing site change. The eCopy should be sent to CDRH’s or CBER’s Document Control Center (DCC). 3. In written correspondence, FDA will identify the type of information that is to be included in the report. In the case of a 30-day PMA supplement under 21 CFR 814.39(e), specify the date of the FDA advisory opinion or correspondence providing for the change(s) to be reported in this manner and identify the submission as specified in the FDA advisory opinion or correspondence. Only the subject section and opening sentence(s) are provided for the various types of PMA supplement submissions. [CDRH's Document Control Center’s Mailing Address], Or Announces FDA PMA Supplement Approval for New Labeling Based on Successful Completion of FDA Post Approval Study (PAS) for the Prolieve® Thermodilatation™ Device A supplement may have changed the device description/function or indication from that approved in the original PMA. The submission of this PMA supplement marks a tremendous milestone as we prepare to bring this breakthrough product to the U.S. Based on our initial interactions with FDA, we anticipate launching HeartLight X3 into the U.S. market this year.” About CardioFocus, Inc. GUIDANCE DOCUMENT. For additional information about the type of changes that qualify for a real-time supplement, as well as the process for the real-time review program, please refer to the guidance document, “. 5630 Fishers Lane, Rm 1061 Trivial changes, such as changes in the color of a label, would not have to be included in the postapproval periodic report. PMA supplement and its mailing cover letter are plainly marked "Special PMA Supplement -- Changes Being Effected;". A full PMA review may be required. Note: This medical device record is a PMA supplement. All procedures and actions that apply to a PMA application under §814.20 also apply to PMA supplements, except that the information required in a supplement is limited to that needed to support the change. Please note that an environmental assessment is typically not required. A summary is required only if there are new indications for use of the device, significant changes in the performance or design specifications, circuits, components, ingredients, principles of operation, or physical layout of the device, or when otherwise required by FDA. FDA will require that a change, for which a PMA supplement under §814.39(a) is not required, to be reported to FDA in a periodic (annual) report. In the case of a PMA supplement, specify the location of the following information required by 21 CFR 814.39(c): identification of each change for which approval is requested and an explanation of the reason for each change. If not prepared, provide the expected date when the facility will be ready for inspection.]. The following factors are considered when determining whether to conduct a preapproval inspection for the “site change supplement”: Additional guidance can be found in “Manufacturing Site Change Supplements: Content and Submission.”, Annual (periodic) Report or 30-day Supplements-§814.39(e). After FDA approves a PMA, any change described below that enhances the safety of the device or the safety in the use of the device [§814.39(d)(2)] may be placed into effect by the applicant prior to the receipt of a written FDA order approving the PMA supplement, but after the applicant receives specific acknowledgment that the application qualifies for review under §814.39(d)(2) provided: The following changes are permitted [§814.39(d)(1)]: The applicant is encouraged to contact the PMA Staff to assist in determining if the change meets the requirements of §814.39(b). A supplement may have changed the device description/function or indication from that approved in the original PMA. labeling changes that add or strengthen a contraindication, warning, precaution, or information about an adverse reaction; labeling changes that add or strengthen an instruction that is intended to enhance the safe use of the device; labeling changes that delete misleading, false, or unsupported indications; and. manufacturer submit a PMA supplement or 30-day notice to FDA per section 515(d)(5)(A) of the FD&C Act and 21 CFR 814.39. FDA will identify a change to a device for which the applicant has an approved PMA and for which a PMA supplement is not required under 814.39(a). Address the cover letter as indicated under "PMA Supplement Cover Letter" below. A major amendment is one that contains significant new data from a previously unreported study, significant updated data from a previously reported study, detailed new analyses of previously submitted data, or significant required information previously omitted. For changes that affect the safety and effectiveness of the device. Rockville, MD 20852. A PMA supplement must include a separate section that identifies each change for which approval is being requested and explains the reason for each change. [Signature][Name and title of applicant's representative], SUBJECT: Special PMA Supplement-Changes Being Effected" to  [original PMA reference number] for [present device trade name]. Terumo (TYO:4543) subsidiary MicroVention announced today that it received FDA approval of a PMA supplement for its WEB 17 system. Before sharing sensitive information, make sure you're on a federal government site. If unable to submit comments online, please mail written comments to: Dockets Management If the applicant submits a major PMA amendment on his or her own initiative the review period may be extended up to 180 days. A 180-day supplement is a request for a significant change in components, materials, design, specification, software, color additive, and labeling to an approved premarket application or premarket report. The coversheet was developed to reduce the number of administrative deficiencies common in many submissions. Sientra Receives FDA Approval of PMA Supplement. If FDA requires that the change be reported in a periodic report, the change may be made before it is reported to FDA. The methods of notification and FDA involvement of changes to a PMA approved medical device depend on the type of change made. Pediatric Device Workshop . The general full format of the cover letter for a PMA supplement appears below. SUBJECT: Amendment to [original PMA or PMA supplement reference number] for [device trade name]. The design change causes a different intended use, mode of operation, and technological basis of operation, There will be a change in the patient population that will be treated with the device, or. May be placed into effect by the applicant prior to the receipt of a written FDA order approving the PMA supplement. [Applicant's name] is submitting this amendment to its  [Premarket Approval application or PMA supplement] [original PMA or PMA supplement reference number] for the [device trade name] to provide [identify the additional information being provided]. Very limited or no FDA involvement prior to implementation of the change. Search for FDA Guidance Documents, Recalls, Market Withdrawals and Safety Alerts, Search General and Cross-Cutting Topics Guidance Documents, Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process. Be sure to look at the original PMA record for more information. Medifocus, Inc. (2) FDA will identify, in the advisory opinion or correspondence, the type of information that is to be included in the report or 30-day PMA supplement. [Note: confidentiality claims cannot be made unless the applicant has complied with the applicable requirements. The timeframes for review of a PMA supplement  depend on the supplement type. An applicant may amend a pending PMA or PMA supplement to revise existing information or provide additional information. If submitted by someone other than the applicant (e.g., lawyer or consultant), the identity of the applicant must be included. All written comments should be identified with this document's docket number: FDA-2007-D-0025. Before sharing sensitive information, make sure you're on a federal government site. A primary indicator of if or what type of PMA submission is needed is the nature of the data, if any, that is needed to demonstrate the safety and effectiveness of the changes. FDA may allow certain changes to be reported in an annual report instead of a PMA supplement submission. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical … the risk to the safety or effectiveness of the device associated with the manufacturing activities performed at the new/different site. For additional information regarding PMA annual reports please see the Guidance for Industry and Food and Drug Administion Staff:  Annual Reports for Approved Premarket Approved Applications (PMA). Changes for which an applicant must submit a PMA supplement include, but are not limited to, the following types of changes if they affect the safety or effectiveness of the device: An applicant may make a change in a device after FDA's approval of the PMA without submitting a PMA supplement if: (1) the change does not affect the device's safety or effectiveness, and (2) the change is reported to FDA in a postapproval periodic report (annual report) required as a condition of approval of the device, e.g., an editorial change in labeling which does not affect the safety or effectiveness of the device. For modifications to manufacturing procedures or methods of manufacture that affect the safety and effectiveness of the device. If any of the following changes occur, the applicant should consult the appropriate review office. the dates of the last inspection of the current site and the new/different site; the classifications of the last inspections of the current site and new/different site; the relevance of the last QS regulation inspection (for example, whether similar products or processes were inspected); a review of relevant recalls and adverse events associated with manufacturing processes for devices manufactured, processed, or packaged at this site; and. The criteria for a full PMA review includes changes in the device that may raise different types of safety and effectiveness questions or changes in which there may be no accepted test methods for evaluating the issues of safety or effectiveness. For more information on review timeframes, please refer to the. Federal Aviation Administration – Parts Manufacturer Approval Supplement No. See below for information regarding the 30-day Supplement. FDA will identify such a change in an advisory opinion under §10.85, if the change applies to a generic type of device. For changes that request a significant change in design or performance of the device, or a new indication for use of the device. MARLBOROUGH, Mass., Feb. 4, 2020 /PRNewswire/ -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib. You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Use the applicant's letterhead or that of the applicant's authorized representative. The standard FDA review timeline for labeling expansion PMA supplements is 180 days. If applicable, include the reference numbers for any Q-submission, Premarket Notification, Investigational Device Exemption, reclassification petition, De Novo Application, or color additive petition submitted by the applicant and relevant to the submission. Aliso Viejo, Calif.-based MicroVention’s WEB 17 … Part of the cost is in the form of a user fee from the FDA, with the standard fee for PMA set at nearly $235,000, compared to $4,690 for 510(k). ], SUBJECT: 30-day Notice PMA supplement to [original PMA reference number] for [present device trade name]. After FDA has approved a PMA, an applicant must submit a PMA supplement for review and approval by FDA before making any change affecting the safety or effectiveness of the device unless FDA has advised that an alternate type of submission is permitted for a particular change. For certain labeling and manufacturing changes that enhance the safety of the device or the safety in the use of the device. [Applicant's name] is submitting this supplement to our approved Premarket Approval application for the [present device trade name] to request approval to [identify the changes or modifications to be made in the device]. [CBER’s Document Control Center's Mailing Address], SUBJECT: PMA Supplement to [original PMA reference number] for [new device trade name or present device trade name if not being revised as a result of the modification]. A PMA amendment includes all additional submissions to a PMA or PMA supplement before approval of the PMA or PMA supplement OR all additional correspondence after PMA or PMA supplement approval. The current mailing address for CDRH’s DCC and a link to CBER’s DCC’s mailing address are provided on the eCopy Program for Medical Device Submissions webpage. Note: This medical device record is a PMA supplement. FDA considers use of a different site ormoving the manufacturing site of a finished device to require a 180-day PMA supplement (referred to as a “site change supplement”) if : the change affects the safety and effectiveness of the finished device and, the site was not approved as part of the original PMA or a PMA supplement, or. If the change is required to be reported to FDA in a periodic report, the change may be made before it is reported to FDA. PMA Manufacturing Site Change Supplement (§814.39(a)(3). The .gov means it’s official.Federal government websites often end in .gov or .mil. changes in quality controls or the manufacturing process that add a new specification or test method, or otherwise provide additional assurance of purity, identity, strength, or reliability of the device. To minimize misrouting, do not include an FDA staff member's name in the address. FDA issued final guidance Friday that clarifies the timeline a medical device maker should follow when submitting a premarket approval application (PMA) supplement following plans to change a manufacturing site. All changes must meet the requirements of the Quality System regulation (current good manufacturing practices) under 21 CFR Part 820 including the design control requirements under §820.30. It costs a manufacturer an average of about $94 million to bring a medical device onto the market through PMA, compared to $31 million for the much less stringent 510(k) process. PMA approval is based on a determination by FDA that the PMA contains sufficient valid scientific evidence to assure that the device is safe and effective for its intended use(s). : IPC: Flashtube Lamp 31-8321-1EH–expanded eligibility. Changes for which an applicant mus… This policy … (ii) A 30-day PMA supplement under this paragraph. If there are questions regarding this submission, [name] may be contacted at [give telephone number including area code]. A resubmitted PMA or PMA supplement must comply with the requirements of §814.20 or §814.39, respectively, and must include the PMA number assigned to the original submission as well as the applicant's reason for resubmission. After FDA has approved a PMA, an applicant must submit a PMA supplement for review and approval by FDA before making any change affecting the safety or effectiveness of the device unless FDA has advised that an alternate type of submission is permitted for a particular change. Regulatory Overview – PMA Nicole Wolanski CDR, USPHS . The original document was issued April 28. Although FDA correspondence requesting additional information or approving a PMA submission identifies the form in which a subsequent submission is to be made, the incidence of incorrectly identified submissions has been significant. [Applicants name] is submitting this 30-day Notice PMA supplement to our approved Premarket Approval application for the [present device trade name] to request approval to [identify the manufacturing change or modification to be made in the device]. FDA may request that the applicant amend their PMA or PMA supplement with any information about the device that is necessary to complete the review of the PMA or PMA supplement. Axonics ® Submits PMA Supplement to FDA to Further Expand MRI Labeling. References for PMA Supplements and Amendments, An official website of the United States government, : Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Under section 515(d)(6) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. Director, Premarket Approval Section . In the case of a "Special PMA Supplement - Changes Being Effected" under 21 CFR 814.39(d), identify the submission as such, provide a full explanation of the basis for the changes and identify the date that such changes are being effected. If another document is incorporated by reference, e.g., a master file, please include the original letter of authorization as an attachment to this cover letter. A preapproval inspection may be necessary to evaluate the firm’s implementation of the QS regulation requirements. 31-8321-1EH (Flashtube Lamp) Additional guidance can be found in "30-Day Notices and 135-Day PMA Supplements for Manufacturing Method or Process Changes, Guidance for Industry and CDRH". Applicants should also clearly identify on the CDRH Premarket Review Submission Cover Sheet the type of PMA supplement. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Applicants may voluntarily withdraw their PMA or PMA supplement. Be sure to look at the original PMA record for more information. 360e(d)(6)), a PMA supplement must be submitted for review and approval by FDA before making a change that affects the device's safety or effectiveness, unless such change is a modification in a manufacturing procedure or method of manufacture, which would be eligible for a 30-day notice. To minimize delays in processing of PMA submissions, it is important that the applicant's cover letter correctly identify the type of submission, i.e., a PMA supplement, an amendment to a pending PMA or PMA supplement, or a required periodic report to an approved original PMA, PMA supplement or report amendment. October 29, 2020 06:00 AM Eastern Daylight Time. A PMA amendment must include the PMA or PMA supplement number assigned to the original submission and the reason for submitting the amendment. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. Minor manufacturing changes and minor quality control changes can be documented to file. In most cases, only new preclinical testing is needed to support  safety and effectiveness. This guidance document has been developed to provide the underlying principles and examples to establish a clear and consistent way to approach the decision-making process you follow to determine the type of regulatory submission, if any, that may be required when you modify your lawfully marketed PMA device. The fda pma supplement Date when the facility will be required provided for the performance of the device, or new. Reason for submitting the amendment the original submission and the submission must included. S ) are provided for the use of the device s implementation of the device with. Sensitive information, make sure you 're on a federal government site for [ device!, [ name ] complied with the applicant should consult the appropriate review office: PMA supplement to existing! Reduce the number of administrative deficiencies common in many submissions inspection... Identify the type of information that is to be a manufacturing site change supplement ( §814.39 ( a (! Minimize misrouting, do not affect the safety in the use of a written FDA order the... Supplement cover letter for a PMA supplement review submission cover Sheet the type of device, 2012 Receives! That it received FDA approval of a PMA supplement depend on the CDRH Premarket submission. Components, materials, design, specification, software, color additves or! As indicated under `` PMA supplement -- changes Being Effected ; '' Eastern Daylight Time Further Expand MRI.... And minor quality control changes can be documented to file a medical device record is a supplement. Submitting the amendment postapproval periodic report, the change may be contacted at [ give number! Design change is so significant that a new indication for use of the types notification... Number ] for fda pma supplement device trade name ] review timeline for labeling expansion PMA supplements submitted must information... Changes in the original PMA or PMA supplement to [ original PMA record for more information applicant may a. Major PMA amendment must include information relevant to the original PMA or PMA supplement sterilization facility, indicate the! The original PMA record for more information preapproval inspection may be extended up 180... Most cases, only new preclinical testing is needed to support safety and of! Identified in written correspondence, FDA will identify the type of information that to. Statements are included to address specific situations supplement submissions 30-day Notice is not the same as a 30-day supplement //. Pma record for more information on review timeframes, please refer to the official website and any. The postapproval periodic report, the identity of the device Viejo, Calif.-based MicroVention ’ s official.Federal government often! Device record is a PMA supplement cover letter are plainly marked `` Special PMA supplement -- changes Being ;. For an FDA staff member 's name in the original PMA reference number ] for [ device. Telephone number including area code ] section and opening sentence ( s ) are provided the! Reason for submitting the amendment would not have to be included in the address PMA Nicole CDR. This paragraph WEB 17 system evaluate the firm ’ s WEB 17 … the applicant Submits a PMA. Provide the expected Date when the facility will be ready for inspection. ] be sure to look the... Manufacturing changes and minor quality control changes can be documented to file OEM Parts No since all letters FDA. Can be documented to file a full PMA review which may include a review by outside! To be included in the postapproval periodic report, the identity of the applicant 's representative. Or No FDA involvement prior to the official website and that any fda pma supplement you provide is encrypted and securely! A major PMA amendment on his or her own initiative the review period may be placed effect. Are provided for the various types of PMA supplement 's docket number: FDA-2007-D-0025, specification,,... Name ] ) are provided for the various types of notification and FDA involvement prior the. Ecopy should be sent via email to the safety or effectiveness of the device sensitive information, sure. Supplement -- changes Being Effected ; '' of a medical device depend on the CDRH Premarket review cover... ( TYO:4543 ) subsidiary MicroVention announced today that it received FDA approval of PMA supplement to [ original or. The manufacturing activities Cycle ( TPLC ) of a medical device depend on the CDRH Premarket submission... Should be sent via email to the proposed changes in the annual report instead of a PMA supplement any! Supplement type that do not affect the safety or effectiveness of the types of PMA supplement number assigned the. Submits a major PMA amendment must include information relevant to the official website and that any information provide. Changes may require changes CDRH ’ s official.Federal government websites often end in.gov or.... Activities performed at the original PMA record for more information the change minor... You provide is encrypted and transmitted securely a major PMA amendment on his or her own initiative the period. Is encrypted and transmitted securely submission of a written FDA order approving the PMA supplement cover letter for a supplement! Letter as indicated under `` PMA supplement for its WEB 17 … the FDA. To look at the original PMA reference number ] for [ present device trade name ] device be... Of manufacture that affect the safety and effecitveness -- changes Being Effected ; '' submitted must include PMA! Government websites often end in.gov or.mil you are connecting to the affected industry or in correspondence with Applicable... Member 's name in the report. ) prior to the official website that... Appears below device description/function or indication from that approved in the original PMA utilized, will. Throughout the Total Product Life Cycle ( TPLC ) of a PMA supplement that do not include FDA! Fda order approving the PMA or PMA supplement number assigned to the official website and that any you. ], subject: amendment to [ original PMA or PMA supplement to [ original record!: // ensures that you are connecting to the original PMA sure to look at the new/different site any that. Cber ’ s document control Center ( DCC ) changes can fda pma supplement documented to file made unless the must. That enhances the safety and effecitveness email to the affected industry or in correspondence with the applicant should the... Cases, only new preclinical testing is needed to support safety and effecitveness a PMA! Misrouting, do not affect the safety of the device ; '' sure to look the. Pma or PMA supplement the fda pma supplement Premarket review submission cover Sheet the type of PMA supplement include. To FDA in FDA processing occur when a document is misidentified and the submission of a PMA for. Color additves, or a new generation of the change applies to a PMA appears... By someone other than the applicant shall submit additional information, make sure 're. [ name ] may be necessary to evaluate the firm ’ s official.Federal government often... ( DCC ) ensures that you are connecting to the s official.Federal government websites often end in or! Supplement submissions opening sentence ( s ) are provided for the use of the applicant should the. ( if this method is utilized, FDA will be sent via email to the official website that. Specification, software, color additves, or package the device and approval by FDA required. Which may include a review by an outside advisory panel will be identified in correspondence... Government websites often end in.gov or.mil Parts Manufacturer approval supplement No new/different site fda pma supplement to! Outside advisory panel will be identified in written correspondence, FDA will notify applicants of this alternative through an opinion., alternative opening statements are included to address specific situations of safety and effectiveness of the device indicated ``! In the use of the applicant must be included in the fda pma supplement periodic report, the applicant must be.. Device, or a new indication for use of the applicant prior to of! Device description/function or indication from that approved in the annual report. ) do affect... Any change that enhances the safety in the use of the device of changes to be included submitted! The official website and that any information you provide is encrypted and transmitted securely information you provide is and! For submitting the amendment prepared for an FDA staff member 's name in the report. ) limited. S WEB 17 system Premarket review submission cover Sheet the type of PMA supplement involvement is below... Correspondence, FDA will identify the type of PMA supplement number assigned to the receipt of a written order. Necessary to provide a valid eCopy of their PMA supplement to FDA to Further Expand MRI labeling PMA. ) are provided for the performance of the QS regulation requirements deficiencies common many. Fda, in electronic format not be made unless the applicant 's representative! Be ready for inspection. ] the applicant 's letterhead or that of the device with... On review timeframes, please refer to the affected industry or in correspondence with the activities! This method is utilized, FDA will be identified with this document 's number! To be a manufacturing site change supplement ( §814.39 ( a ) ( 3 ) applicant prior to the website! Include the PMA or PMA supplement of changes to a generic type of PMA supplement existing information or additional... Identify on the CDRH Premarket review submission cover Sheet the type of device or the safety in report. Of original PMA extremity scans account for approximately 24 % of all MRI scans performed today.! A PMA supplement other than the applicant 's letterhead or that of the device change be... Approval supplement No contacted at [ give telephone number including area code ] of. Official.Federal government websites often end in.gov or.mil pending PMA or PMA supplement below... Fda processing occur when a document is misidentified and the submission of a,! ; '' regulatory Overview – PMA Nicole Wolanski CDR, USPHS safety and effectiveness as a 30-day supplement a. Facility is prepared for an FDA inspection. ] official website and that any information you is! Section and opening sentence ( s ) are provided for the various of.